(Q36800963)

16 August 2017

1 reference

title

The immune-mediated alteration of serotonin and glutamate: towards an integrated view of depression (English)

1 reference

16 August 2017

0 references

Müller N

1

1 reference

16 August 2017

Schwarz MJ

series ordinal

2

1 reference

16 August 2017

language of work or name

English

0 references

publication date

24 April 2007

1 reference

16 August 2017

1 reference

16 August 2017

volume

12

1 reference

16 August 2017

issue

11

1 reference

16 August 2017

page(s)

988-1000

1 reference

Exacerbation of schizophrenia associated with amantadine

16 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

Beyond monoamines: glutamatergic function in mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

Plasma and platelet excitatory amino acids in psychiatric disorders.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

CSF corticotropin-releasing hormone in depressed patients and normal control subjects

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

Liver and brain tryptophan metabolism following hydrocortisone administration to rats and gerbils

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

Japanese encephalitis virus up-regulates expression of macrophage migration inhibitory factor (MIF) mRNA in the mouse brain

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

Quercetin, a phytoestrogen and dietary flavonoid, activates different membrane-bound guanylate cyclase isoforms in LLC-PK1 and PC12 cells.

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

CSF Prostaglandin Levels in Depressed and Schizophrenic Patients

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

Cyloserine as an antidepressant agent

21 January 2018

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Effects of MK-801 and antidepressant drugs in the forced swimming test in rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Functional antagonists at the NMDA receptor complex exhibit antidepressant actions

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Prolonged effect of an anesthetic dose of ketamine on behavioral despair

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The involvement of glutamate in the pathophysiology of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Possible use of amantadine in depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Amantadine as augmentation therapy in the management of treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Small-dose ketamine improves the postoperative state of depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Antidepressant effect of ketamine during ECT.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Riluzole enhances glutamate uptake in rat astrocyte cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Beneficial effects of the antiglutamatergic agent riluzole in a patient diagnosed with obsessive-compulsive disorder and major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Subtype-specific alterations of gamma-aminobutyric acid and glutamate in patients with major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Riluzole augmentation for treatment-resistant depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

An open-label trial of riluzole in patients with treatment-resistant major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

An open-label trial of the glutamate-modulating agent riluzole in combination with lithium for the treatment of bipolar depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Dizocilpine (MK-801) increases not only dopamine but also serotonin and norepinephrine transmissions in the nucleus accumbens as measured by microdialysis in freely moving rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Systemic PCP treatment elevates brain extracellular 5-HT: a microdialysis study in awake rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased serum glutamate in depressed patients

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Plasma and platelet amino acid concentrations in patients affected by major depression and under fluvoxamine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Serum levels of excitatory amino acids, serine, glycine, histidine, threonine, taurine, alanine and arginine in treatment-resistant depression: modulation by treatment with antidepressants and prediction of clinical responsivity.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Alterations in the N-methyl-d-asparatate (NMDA) receptor complex in the frontal cortex of suicide victims

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The NR1 subunit of the glutamate/NMDA receptor in the superior temporal cortex in schizophrenia and affective disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Decreased hippocampal NMDA, but not kainate or AMPA receptors in bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Progressive slowing of reaction time and increasing cerebrospinal fluid concentrations of quinolinic acid in HIV-infected individuals

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Quinolinic acid in cerebrospinal fluid and serum in HIV-1 infection: relationship to clinical and neurological status

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Sources of the neurotoxin quinolinic acid in the brain of HIV-1-infected patients and retrovirus-infected macaques

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

IDO and interferon-alpha-induced depressive symptoms: a shift in hypothesis from tryptophan depletion to neurotoxicity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Size of burden of schizophrenia and psychotic disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

An evaluation of the role of extracellular amino acids in the delayed neurodegeneration induced by quinolinic acid in the rat striatum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

NMDA and non-NMDA receptor-mediated excitotoxicity are potentiated in cultured striatal neurons by prior chronic depolarization

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine–serotonin interaction through IDO: a neurodegeneration hypothesis of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Modulation of neopterin formation and tryptophan degradation by Th1- and Th2-derived cytokines in human monocytic cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

A two-step induction of indoleamine 2,3 dioxygenase (IDO) activity during dendritic-cell maturation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Indolamine 2,3-dioxygenase is expressed in the CNS and down-regulates autoimmune inflammation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The role of IFN-gamma and TNF-alpha-responsive regulatory elements in the synergistic induction of indoleamine dioxygenase

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interferons and indoleamine 2,3-dioxygenase: role in antimicrobial and antitumor effects

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Tolerance, DCs and tryptophan: much ado about IDO

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Tryptophan catabolism and T-cell tolerance: immunosuppression by starvation?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Inhibition of T cell proliferation by macrophage tryptophan catabolism

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Regulation of the kynurenine metabolic pathway by interferon-gamma in murine cloned macrophages and microglial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine-induced sickness behavior: where do we stand?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine-associated emotional and cognitive disturbances in humans

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Endotoxin-induced changes in food consumption in healthy volunteers are associated with TNF-alpha and IL-6 secretion.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Psychiatric symptoms in patients with chronic hepatitis C receiving interferon alfa-2b therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Suicidal ideation during interferon-alpha2b and ribavirin treatment of patients with chronic hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Psychological and behavioural effects of interferons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Correlation between sICAM-1 and depressive symptoms during adjuvant treatment of melanoma with interferon-alpha.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

A prospective study of the incidence and open-label treatment of interferon-induced major depressive disorder in patients with hepatitis C.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Association between decreased serum tryptophan concentrations and depressive symptoms in cancer patients undergoing cytokine therapy.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interferon-alpha-induced changes in tryptophan metabolism. relationship to depression and paroxetine treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokines and psychopathology: lessons from interferon-alpha

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Can rodents be used to model interferon-α-induced depressive symptoms?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokines sing the blues: inflammation and the pathogenesis of depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Investigations of the cellular immunity during depression and the free interval: evidence for an immune activation in affective psychosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased plasma concentrations of interleukin-6, soluble interleukin-6, soluble interleukin-2 and transferrin receptor in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Plasma-soluble interleukin-2 and transferrin receptor in schizoprenia and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immune correlates of depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immune and hormonal activity in adults suffering from depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased serum tumor necrosis factor alpha concentrations in major depression and multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Depression and immunity: a meta-analytic review

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Major depressive disorder is associated with elevated monocyte counts

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Different immune patterns in melancholic and non-melancholic major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Urinary excretion of biopterin and neopterin in psychiatric disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Neopterin measurement provides evidence of altered cell-mediated immunity in patients with depression, but not with schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased neopterin and interferon-gamma secretion and lower availability of L-tryptophan in major depression: further evidence for an immune response

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immune markers in fibromyalgia: comparison with major depressed patients and normal volunteers.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Evidence for an immune response in major depression: a review and hypothesis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokines and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Relationships between interleukin-6 activity, acute phase proteins, and function of the hypothalamic-pituitary-adrenal axis in severe depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Possible association between -G308A tumour necrosis factor-alpha gene polymorphism and major depressive disorder in the Korean population.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Analysis of IL-1alpha, IL-1beta, and IL-1RA [correction of IL-RA] polymorphisms in dysthymia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interleukin-1beta (IL-1beta) gene and increased risk for the depressive symptom-dimension in schizophrenia spectrum disorders.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased CD56+ natural killer cells and related cytokines in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Th1, Th2, and Th3 cytokine alterations in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Th2 cytokine response in Major Depressive Disorder patients before treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Indicators of immune activation in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Lymphocyte subsets and lymphokine production in patients with melancholic versus nonmelancholic depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cerebrospinal cytokine levels in patients with acute depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine production and treatment response in major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased serum tumor necrosis factor-alpha levels and treatment response in major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Inflammatory markers and depressed mood in older persons: results from the Health, Aging and Body Composition study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cutaneous glucocorticoid receptor sensitivity and pro-inflammatory cytokine levels in antidepressant-resistant depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Differences in interleukins' patterns between dysthymia and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Raised levels of plasma interleukin-1beta in major and postviral depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increase in Interleukin-1β in Late-Life Depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine profiles in women with different subtypes of major depressive disorder.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokines and serotonin transporter in patients with major depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Acute phase proteins in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased serum IL-6 and IL-1 receptor antagonist concentrations in major depression and treatment resistant depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interleukin-6-(IL-6) plasma levels in depression and schizophrenia: comparison between the acute state and after remission

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The inflammatory response system and the availability of plasma tryptophan in patients with primary sleep disorders and major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immune consequences of the spontaneous pro-inflammatory status in depressed elderly patients.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Dissociation of inflammatory markers and natural killer cell activity in major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Major depression is associated with significant diurnal elevations in plasma interleukin-6 levels, a shift of its circadian rhythm, and loss of physiological complexity in its secretion: clinical implications

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Higher than normal plasma interleukin-6 concentrations in cancer patients with depression: preliminary findings

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Plasma levels of interleukin-1 beta and interleukin-6 in schizophrenia, other psychoses, and affective disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Blood levels of cytokines in elderly patients with major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Plasma concentrations of interleukin-1beta, interleukin-6, soluble interleukin-2 receptor and tumor necrosis factor alpha of depressed patients in Japan

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Plasma levels of cytokines and soluble cytokine receptors in psychiatric patients upon hospital admission: effects of confounding factors and diagnosis.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interleukin-6 and the soluble IL-6 receptor are decreased in cerebrospinal fluid of geriatric patients with major depression: no alteration of soluble gp130

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cerebrospinal fluid interleukin (IL)-6 in unipolar major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Fever and hypothermia in systemic inflammation: recent discoveries and revisions.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immune activation in non-treated suicidal major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Hypothesis: low serum cholesterol, suicide, and interleukin-2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased soluble interleukin-2 receptor concentrations in suicide attempters.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Possible association of interleukin-2 treatment with depression and suicide

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Different activation patterns of proinflammatory cytokines in melancholic and non-melancholic major depression are associated with HPA axis activity

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The Association Between Major Depression and Levels of Soluble Intercellular Adhesion Molecule 1, Interleukin-6, and C-Reactive Protein in Patients With Recent Acute Coronary Syndromes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Elevation in Late-Life Depression of Intercellular Adhesion Molecule-1 Expression in the Dorsolateral Prefrontal Cortex

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Soluble intercellular adhesion molecule-1 in cerebrospinal fluid: an indicator for the inflammatory impairment of the blood-cerebrospinal fluid barrier

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Neuroinvasion by simian immunodeficiency virus coincides with increased numbers of perivascular macrophages/microglia and intrathecal immune activation.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Characterization of type 1 and type 2 cytokine production profile in physiologic and pathologic human pregnancy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Quantitative analysis of peripheral blood Th0, Th1, Th2 and the Th1:Th2 cell ratio during normal human pregnancy and preeclampsia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Depressive and anxiety symptoms in the early puerperium are related to increased degradation of tryptophan into kynurenine, a phenomenon which is related to immune activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Pregnancy in patients with rheumatic disease: anti-inflammatory cytokines increase in pregnancy and decrease post partum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The pattern of mental change and body weight change in the first post-partum week

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Prevalence of depressive symptoms in late pregnancy and postpartum

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Measurement of tryptophan, kynurenine and neopterin in women with and without postpartum blues

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

A multivariate investigation of postpartum mood disturbance

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Depression, immunocompetence, and prostaglandins of the E series

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Increased level of salivary prostaglandins in patients with major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Actions of the tricyclic antidepressant clomipramine on responses to pressor agents. Interactions with prostaglandin E2

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Fluoxetine and amitriptyline inhibit nitric oxide, prostaglandin E2, and hyaluronic acid production in human synovial cells and synovial tissue cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Life events and depression. A controlled study

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Discovering endophenotypes for major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Depression and cortisol responses to psychological stress: a meta-analysis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immunoregulatory feedback between interleukin-1 and glucocorticoid hormones

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Corticotropin-releasing factor-producing neurons in the rat activated by interleukin-1.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Brain IL-1-induced immunosuppression occurs through activation of both pituitary-adrenal axis and sympathetic nervous system by corticotropin-releasing factor

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Immunoregulators in the nervous system

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interleukin 1alpha (IL-1alpha) induced activation of p38 mitogen-activated protein kinase inhibits glucocorticoid receptor function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interleukin-6 and ACTH act synergistically to stimulate the release of corticosterone from adrenal gland cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Exposure to physical and psychological stressors elevates plasma interleukin 6: relationship to the activation of hypothalamic-pituitary-adrenal axis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Effects of repeated stress on expression of interleukin-6 (IL-6) and IL-6 receptor mRNAs in rat hypothalamus and midbrain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokines: abnormalities in major depression and implications for pharmacological treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Astroglial plasticity in the hippocampus is affected by chronic psychosocial stress and concomitant fluoxetine treatment.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Role of interleukin-1 beta in impairment of contextual fear conditioning caused by social isolation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Exposure to acute stress induces brain interleukin-1beta protein in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Macrophage migration inhibitory factor in the cerebrospinal fluid of patients with conventional and optic-spinal forms of multiple sclerosis and neuro-Behçet's disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Relationship between cyclooxygenase-2 and nitric oxide synthase-2 in rat cortex after stress

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

A mechanism for glucocorticoid toxicity in the hippocampus: increased neuronal vulnerability to metabolic insults.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Exposure to excess glucocorticoids alters dendritic morphology of adult hippocampal pyramidal neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Glucocorticoids mediate the stress-induced extracellular accumulation of glutamate

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Physiological elevations of glucocorticoids potentiate glutamate accumulation in the hippocampus.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Corticosterone acutely prolonged N-methyl-d-aspartate receptor-mediated Ca2+ elevation in cultured rat hippocampal neurons

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Stress-induced elevation of glucocorticoids increases microglia proliferation through NMDA receptor activation

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Is there a balance between microglia and astrocytes in regulating Th1/Th2-cell responses and neuropathologies?

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Regulation of T-cell responses by CNS antigen-presenting cells: different roles for microglia and astrocytes

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Glial reduction in the subgenual prefrontal cortex in mood disorders

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Morphometric evidence for neuronal and glial prefrontal cell pathology in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Reductions in neuronal and glial density characterize the dorsolateral prefrontal cortex in bipolar disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Depression: what we can learn from postmortem studies

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Disease-specific alterations in frontal cortex brain proteins in schizophrenia, bipolar disorder, and major depressive disorder. The Stanley Neuropathology Consortium

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Glial fibrillary acidic protein immunoreactivity in the prefrontal cortex distinguishes younger from older adults in major depressive disorder

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Age-dependent reductions in the level of glial fibrillary acidic protein in the prefrontal cortex in major depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Glial fibrillary acidic protein in late life major depressive disorder: an immunocytochemical study.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Glial fibrillary acidic protein is reduced in cerebellum of subjects with major depression, but not schizophrenia

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Regulation of glutamate transporters in health and disease

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Fast removal of synaptic glutamate by postsynaptic transporters

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

1 reference

7 January 2021

Effects of zimeldine and its metabolites, clomipramine, imipramine and maprotiline in experimental allergic neuritis in Lewis rats

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Effect of monoamine reuptake inhibiting antidepressants on major histocompatibility complex expression on macrophages in normal rats and rats with experimental allergic neuritis (EAN)

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The immune system, depression and the action of antidepressants

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Negative Immunoregulatory Effects of Antidepressants Inhibition of Interferon-γ and Stimulation of Interleukin-10 Secretion

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Anti-Inflammatory effects of antidepressants through suppression of the interferon-gamma/interleukin-10 production ratio.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Treatment of depression is associated with suppression of nonspecific and antigen-specific T(H)1 responses in multiple sclerosis

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine production and serum proteins in depression

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Effects of antidepressants on the production of cytokines

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Amitriptyline and nortriptyline inhibit interleukin-1 release by rat mixed glial and microglial cell cultures

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Interleukin-6 serum levels in depressed patients before and after treatment with fluoxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

IL-6 levels decrease with SSRI treatment in patients with major depression.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Plasma levels of adiponectin and tumor necrosis factor-alpha in patients with remitted major depression receiving long-term maintenance antidepressant therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Cytokine-induced changes in mood and behaviour: implications for 'depression due to a general medical condition', immunotherapy and antidepressive treatment

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Raised plasma levels of tumor necrosis factor alpha in patients with depression: normalization during electroconvulsive therapy

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Sleep associated regulation of T helper 1/T helper 2 cytokine balance in humans.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Inhibition of COX-2 reduces the age-dependent increase of hippocampal inflammatory markers, corticosterone secretion, and behavioral impairments in the rat.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Inhibition of COX-2 by celecoxib enhances glucocorticoid receptor function

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Lipopolysaccharide injected into the cerebral ventricle evokes fever through induction of cyclooxygenase-2 in brain endothelial cells.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Effect of rofecoxib on nociception and the serotonin system in the rat brain

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The non-steroidal anti-inflammatory drug diclofenac sodium attenuates IFN-alpha induced alterations to monoamine turnover in prefrontal cortex and hippocampus

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Hippocampal upregulation of the cyclooxygenase-2 gene following neonatal clomipramine treatment (a model of depression).

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Inhibitors of cyclooxygenase-2, but not cyclooxygenase-1 provide structural and functional protection against quinolinic acid-induced neurodegeneration

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Improved control of osteoarthritis pain and self-reported health status in non-responders to celecoxib switched to rofecoxib: results of PAVIA, an open-label post-marketing survey in Spain.

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

The cyclooxygenase-2 inhibitor celecoxib has therapeutic effects in major depression: results of a double-blind, randomized, placebo controlled, add-on pilot study to reboxetine

1 reference

https://api.crossref.org/works/10.1038%2FSJ.MP.4002006

7 January 2021

Identifiers

DOI

10.1038/SJ.MP.4002006

1 reference

Dimensions Publication ID

16 August 2017

1027917757

0 references

1 reference